# A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.

> **NCT04277897** · PHASE1 · UNKNOWN · sponsor: **Xi'an Xintong Pharmaceutical Research Co.,Ltd.** · enrollment: 69 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Hepenofovir Fumarate Tablets Single Dose
- **DRUG:** Placebo
- **DRUG:** Hepenofovir Fumarate Tablets Dose4

## Key facts

- **NCT ID:** NCT04277897
- **Lead sponsor:** Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-15
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277897, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04277897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*